Pseudomonas aeruginosa bacteraemia: Independent risk factors for mortality and impact of resistance on outcome

Journal of Medical Microbiology

Volumn 63, Issue , 2014, Pages 1679-1687

  Dantas, Raquel Cavalcanti ^a   Ferreira, Melina Lorraine ^a   Gontijo Filho, Paulo Pinto ^a   Ribas, Rosineide Marques ^a  

^a FEDERAL UNIVERSITY OF UBERLÂNDIA   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE; CARBAPENEM; CEFEPIME; CEFTAZIDIME; CIPROFLOXACIN; FLUOROQUINOLONE; GENTAMICIN; IMIPENEM; LEVOFLOXACIN; MEROPENEM; METALLO BETA LACTAMASE; PIPERACILLIN PLUS TAZOBACTAM; QUINOLONE DERIVATIVE; UNCLASSIFIED DRUG; BACTERIAL DNA;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ANTIMICROBIAL THERAPY; ARTICLE; BACTEREMIA; BACTERIAL STRAIN; BACTERIUM ISOLATE; BRAZILIAN; DRUG USE; FEMALE; GENE; HEMODIALYSIS; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; POLYMERASE CHAIN REACTION; PSEUDOMONAS AERUGINOSA BACTEREMIA; RETROSPECTIVE STUDY; RISK FACTOR; TERTIARY CARE CENTER; TRACHEOSTOMY; ADOLESCENT; ADULT; AGED; BRAZIL; CHILD; DRUG EFFECTS; GENETICS; INFANT; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MIDDLE AGED; NEWBORN; PRESCHOOL CHILD; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; SURVIVAL; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BACTEREMIA; BRAZIL; CHILD; CHILD, PRESCHOOL; DNA, BACTERIAL; DRUG RESISTANCE, BACTERIAL; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; POLYMERASE CHAIN REACTION; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL ANALYSIS; TERTIARY CARE CENTERS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84919372716     PISSN: 00222615     EISSN: None     Source Type: Journal    
DOI: 10.1099/jmm.0.073262-0     Document Type: Article

References (37)

1. Andrade, S. S., Jones, R. N., Gales, A. C. & Sader, H. S. (2003). Increasing prevalence of antimicrobial resistance among Pseudomonas aeruginosa isolates in Latin American medical centres: 5 year report of the SENTRY Antimicrobial Surveillance Program (1997–2001). J Antimicrob Chemother 52, 140–141.
2. Arakawa, Y., Shibata, N., Shibayama, K., Kurokawa, H., Yagi, T., Fujiwara, H. & Goto, M. (2000). Convenient test for screening metallo-b-lactamase-producing gram-negative bacteria by using thiol compounds. J Clin Microbiol 38, 40–43.
3. Baumgart, A. M., Molinari, M. A. & Silveira, A. C. (2010). Prevalence of carbapenem resistant Pseudomonas aeruginosa and Acinetobacter baumannii in high complexity hospital. Braz J Infect Dis 14, 433–436.
4. Blanc, D. S., Francioli, P. & Zanetti, G. (2007). Molecular epidemiology of Pseudomonas aeruginosa in the intensive care units – a review. Open Microbiol J 1, 8–11.
5. Caulcott, C. A., Brown, M. R. W. & Gonda, I. (1984). Evidence for small pores in the outer membrane of Pseudomonas aeruginosa. FEMS Microbiol Lett 21, 119–123.
6. Cezário, R. C., Duarte De Morais, L., Ferreira, J. C., Costa-Pinto, R. M., da Costa Darini, A. L. & Gontijo-Filho, P. P. (2009). Nosocomial outbreak by imipenem-resistant metallo-b-lactamase-producing Pseudomonas aeruginosa in an adult intensive care unit in a Brazilian teaching hospital. Enferm Infecc Microbiol Clin 27, 269–274.
7. CLSI (2009). Performance Standards for Antimicrobial Susceptibility Testing; 19th Informational Supplement M100-S19. Wayne, PA: Clinical and Laboratory Standards Institute.
8. CLSI (2010). Performance Standards for Antimicrobial Susceptibility Testing; 20th Informational Supplement M100-S20. Wayne, PA: Clinical and Laboratory Standards Institute.
9. CLSI (2011). Performance Standards for Antimicrobial Susceptibility Testing; 21st Informational Supplement M100-S21. Wayne, PA: Clinical and Laboratory Standards Institute.
10. Cosgrove, S. E. (2006). The relationship between antimicrobial resistance and patient outcomes: mortality, length of hospital stay, and health care costs. Clin Infect Dis 42 (Suppl 2), S82–S89.
11. El Amin, N., Giske, C. G., Jalal, S., Keijser, B., Kronvall, G. & Wretlind, B. (2005). Carbapenem resistance mechanisms in Pseudomonas aeruginosa: alterations of porin OprD and efflux proteins do not fully explain resistance patterns observed in clinical isolates. APMIS 113, 187–196.
12. Emori, T. G., Culver, D. H., Horan, T. C., Jarvis, W. R., White, J. W., Olson, D. R., Banerjee, S., Edwards, J. R., Martone, W. J. & other authors (1991). National nosocomial infections surveillance system (NNIS): description of surveillance methods. Am J Infect Control 19, 19–35.
13. Franco, M. R., Caiaffa-Filho, H. H., Burattini, M. N. & Rossi, F. (2010). Metallo-beta-lactamases among imipenem-resistant Pseudomonas aeruginosa in a Brazilian university hospital. Clinics (Sao Paulo) 65, 825–829.
14. Furtado, G. H., Bergamasco, M. D., Menezes, F. G., Marques, D., Silva, A., Perdiz, L. B., Wey, S. B. & Medeiros, E. A. (2009). Imipenem-resistant Pseudomonas aeruginosa infection at a medical-surgical intensive care unit: risk factors and mortality. J Crit Care 24, 625.e9–625.e14.
15. Gilbert, D. N., Moellering, R. C., Eliopoulos, G. M. & Sande, M. A. (2007). The Sanford Guide to Antimicrobial Therapy, 37th edn. Sperryville, VA: Antimicrobial Therapy.
16. Hirsch, E. B. & Tam, V. H. (2010). Impact of multidrug-resistant Pseudomonas aeruginosa infection on patient outcomes. Expert Rev Pharmacoecon Outcomes Res 10, 441–451.
17. Horan, T. C., Andrus, M. & Dudeck, M. A. (2008). CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control 36, 309–332.
18. Joo, E. J., Kang, C. I., Ha, Y. E., Kang, S. J., Park, S. Y., Chung, D. R., Peck, K. R., Lee, N. Y. & Song, J. H. (2011). Risk factors for mortality in patients with Pseudomonas aeruginosa bacteremia: clinical impact of antimicrobial resistance on outcome. Microb Drug Resist 17, 305–312.
19. Kang, C. I., Kim, S. H., Kim, H. B., Park, S. W., Choe, Y. J., Oh, M. D., Kim, E. C. & Choe, K. W. (2003). Pseudomonas aeruginosa bacteremia: risk factors for mortality and influence of delayed receipt of effective antimicrobial therapy on clinical outcome. Clin Infect Dis 37, 745–751.
20. Kang, C. I., Kim, S. H., Park, W. B., Lee, K. D., Kim, H. B., Kim, E. C., Oh, M. D. & Choe, K. W. (2005). Bloodstream infections caused by antibiotic-resistant Gram-negative bacilli: risk factors for mortality and impact of inappropriate initial antimicrobial therapy on outcome. Antimicrob Agents Chemother 49, 760–766.
21. Kiffer, C., Hsiung, A., Oplustil, C., Sampaio, J., Sakagami, E., Turner, P., Mendes, C. & MYSTIC Brazil Group (2005). Antimicrobial susceptibility of Gram-negative bacteria in Brazilian hospitals: the MYSTIC Program Brazil 2003. Braz J Infect Dis 9, 216–224.
22. Laupland, K. B., Parkins, M. D., Church, D. L., Gregson, D. B., Louie, T. J., Conly, J. M., Elsayed, S. & Pitout, J. D. (2005). Population-based epidemiological study of infections caused by carbapenem-resistant Pseudomonas aeruginosa in the Calgary Health Region: importance of metallo-b-lactamase (MBL)-producing strains. J Infect Dis 192, 1606– 1612.
23. Lodise, T. P., Jr, Patel, N., Kwa, A., Graves, J., Furuno, J. P., Graffunder, E., Lomaestro, B. & McGregor, J. C. (2007). Predictors of 30-day mortality among patients with Pseudomonas aeruginosa bloodstream infections: impact of delayed appropriate antibiotic selection. Antimicrob Agents Chemother 51, 3510–3515.
24. Magiorakos, A. P., Srinivasan, A., Carey, R. B., Carmeli, Y., Falagas, M. E., Giske, C. G., Harbarth, S., Hindler, J. F., Kahlmeter, G. & other authors (2012). Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 18, 268–281.
25. Mathee, K., Narasimhan, G., Valdes, C., Qiu, X., Matewish, J. M., Koehrsen, M., Rokas, A., Yandava, C. N., Engels, R. & other authors (2008). Dynamics of Pseudomonas aeruginosa genome evolution. Proc Natl Acad Sci U S A 105, 3100–3105.
26. Morales, E., Cots, F., Sala, M., Comas, M., Belvis, F., Riu, M., Salvado´, M., Grau, S., Horcajada, J. P. & other authors (2012). Hospital costs of nosocomial multi-drug resistant Pseudomonas aeruginosa acquisition. BMC Health Serv Res 12, 122–129.
27. Peña, C., Suarez, C., Gozalo, M., Murillas, J., Almirante, B., Pomar, V., Aguilar, M., Granados, A., Calbo, E. & other authors (2012). Prospective multicenter study of the impact of carbapenem resistance on mortality in Pseudomonas aeruginosa bloodstream infections. Antimicrob Agents Chemother 56, 1265–1272.
28. Rosenthal, V. D., Maki, D. G., Salomao, R., Moreno, C. A., Mehta, Y., Higuera, F., Cuellar, L. E., Arikan, O. A., Abouqal, R., Leblebicioglu, H. & International Nosocomial Infection Control Consortium (2006). Device-associated nosocomial infections in 55 intensive care units of 8 developing countries. Ann Intern Med 145, 582–591.
29. Sader, H. S., Gales, A. C., Pfaller, M. A., Mendes, R. E., Zoccoli, C., Barth, A. & Jones, R. N. (2001). Pathogen frequency and resistance patterns in Brazilian hospitals: summary of results from three years of the SENTRY Antimicrobial Surveillance Program. Braz J Infect Dis 5, 200–214.
30. Scheffer, M. C., Gales, A. C., Barth, A. L., Carmo Filho, J. R. & Dalla-Costa, L. M. (2010). Carbapenem-resistant Pseudomonas aeruginosa: clonal spread in southern Brazil and in the state of Goia´s. Braz J Infect Dis 14, 508–509.
31. Singh, G., Wu, B., Baek, M. S., Camargo, A., Nguyen, A., Slusher, N. A., Srinivasan, R., Wiener-Kronish, J. P. & Lynch, S. V. (2010). Secretion of Pseudomonas aeruginosa type III cytotoxins is dependent on pseudomonas quinolone signal concentration. Microb Pathog 49, 196–203.
32. Souli, M., Galani, I. & Giamarellou, H. (2008). Emergence of extensively drug-resistant and pandrug-resistant Gram-negative bacilli in Europe. Euro Surveill 13, 1–11.
33. Strateva, T. & Yordanov, D. (2009). Pseudomonas aeruginosa – a phenomenon of bacterial resistance. J Med Microbiol 58, 1133–1148.
34. Wirth, F. W., Picoli, S. U., Cantarelli, V. V., Gonçalves, A. L., Brust, F. R., Santos, L. M. & Barreto, M. F. (2009). Metallo-b-lactamase-producing Pseudomonas aeruginosa in two hospitals from southern Brazil. Braz J Infect Dis 13, 170–172.
35. Woodford, N. (2010). Rapid characterization of beta-lactamases by multiplex PCR. Methods Mol Biol 642, 181–192.
36. Xavier, D. E., Picão, R. C., Girardello, R., Fehlberg, L. C. & Gales, A. C. (2010). Efflux pumps expression and its association with porin down-regulation and beta-lactamase production among Pseudomonas aeruginosa causing bloodstream infections in Brazil. BMC Microbiol 10, 217–223.
37. Zavascki, A. P., Barth, A. L., Gonçalves, A. L., Moro, A. L., Fernandes, J. F., Martins, A. F., Ramos, F. & Goldani, L. Z. (2006). The influence of metallo-beta-lactamase production on mortality in nosocomial Pseudomonas aeruginosa infections. J Antimicrob Chemother 58, 387–392.